Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-12-19Clinical Trial Update: Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers [Phase 1, Phase 2]
Phase 1/2 trial evaluating MK-3475 (pembrolizumab) in combination with INCB024360 in various selected cancers; study completed with results …
-
CLINICAL_TRIALS trial_result · 2019-11-13Clinical Trial Update: Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer [Phase 2]
This update reports a Phase 2 neoadjuvant study of carboplatin plus docetaxel in triple-negative breast cancer.
-
CLINICAL_TRIALS trial_result · 2019-11-13Clinical Trial Update: A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread [Phase 2]
Phase 2 clinical trial update investigating cobimetinib combinations with paclitaxel, atezolizumab-based regimens for metastatic triple-nega…
-
CLINICAL_TRIALS trial_result · 2019-10-28Clinical Trial Update: MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment [Phase 1]
Phase 1 trial of MM-398 (Nal-IRI) investigates tumor drug levels and feasibility of using ferumoxytol-enhanced MRI to measure tumor-associat…
-
CLINICAL_TRIALS trial_result · 2019-10-24Clinical Trial Update: Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173) [Phase 1]
Phase 1 trial evaluating pembrolizumab with chemotherapy as neoadjuvant treatment for triple-negative breast cancer has completed with resul…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-10-04Clinical Trial Update: Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients [Phase 2]
Phase 2 trial evaluating pembrolizumab in combination with radiotherapy for metastatic triple-negative breast cancer has completed with resu…
-
CLINICAL_TRIALS trial_result · 2019-09-20Clinical Trial Update: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer [Phase 2]
Phase 2 trial updates trametinib combined with an AKT inhibitor (GSK2141795) in metastatic triple-negative breast cancer; study completed wi…
-
CLINICAL_TRIALS trial_result · 2019-09-10Clinical Trial Update: Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer [Phase 2]
Phase II trial investigating neoadjuvant metronomic chemotherapy in triple-negative breast cancer was terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2019-08-08Clinical Trial Update: A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC [Phase 3]
Phase 3 trial comparing first-line JS001 + nab-paclitaxel vs palbociclib + nab-paclitaxel in advanced recurrent/metastatic triple negative b…
-
CLINICAL_TRIALS trial_result · 2019-06-07Clinical Trial Update: Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients [Phase 2]
Phase 2 clinical trial update investigating carboplatin and eribulin mesylate in triple-negative breast cancer.
-
CLINICAL_TRIALS trial_result · 2019-04-30Clinical Trial Update: Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer [Phase 2]
Phase 2 trial comparing combined apatinib mesylate and vinorelbine versus vinorelbine alone in triple-negative breast cancer.
-
CLINICAL_TRIALS trial_result · 2019-04-29Clinical Trial Update: A Study Of PF-06647263 In Patients With Advanced Solid Tumors [Phase 1]
Phase 1 study of PF-06647263 in advanced solid tumors; terminated with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-03-21Clinical Trial Update: The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency [Phase 3]
Phase 3 trial update comparing dose-dense AC-T versus TP as adjuvant therapy for triple-negative breast cancer with homologous recombination…
-
CLINICAL_TRIALS trial_result · 2019-03-08Clinical Trial Update: Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer [Phase 2]
Phase 2 trial evaluating Glembatumumab Vedotin (CDX-011) in metastatic gpNMB-overexpressing triple-negative breast cancer has completed; res…
-
CLINICAL_TRIALS trial_result · 2019-03-05Clinical Trial Update: Study of Tremelimumab in Patients With Advanced Solid Tumors [Phase 2]
Phase 2 clinical trial update for tremelimumab in advanced solid tumors completed with posted results in 2019.
-
CLINICAL_TRIALS research · 2019-02-20Clinical Trial Update: Triple Negative Breast Cancer Trial [Phase 3]
A Phase 3 trial investigating triple-negative breast cancer is sponsored by the Institute of Cancer Research in the United Kingdom. The curr…
-
CLINICAL_TRIALS trial_result · 2019-02-01Clinical Trial Update: CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) [Phase 1, Phase 2]
This document reports the completion of a Phase 1/Phase 2 clinical trial evaluating seviteronel, a CYP17 lyase and androgen receptor inhibit…
-
CLINICAL_TRIALS trial_result · 2019-01-23Clinical Trial Update: BKM120 For Triple Negative Breast Cancer [Phase 2]
A Phase 2 trial of buparlisib (BKM120) for triple-negative breast cancer has completed and results were posted in January 2019.
-
CLINICAL_TRIALS trial_result · 2019-01-10Clinical Trial Update: Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer [Phase 4]
A Phase 4 trial update evaluating albumin-bound paclitaxel followed by epirubicin with cyclophosphamide in triple-negative breast cancer is …
-
CLINICAL_TRIALS trial_result · 2018-12-14Clinical Trial Update: Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer [Phase 2]
Phase 2 trial comparing apatinib plus capecitabine versus capecitabine alone as maintenance therapy in advanced triple-negative breast cance…
-
CLINICAL_TRIALS trial_result · 2018-12-04Clinical Trial Update: Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer [Phase 2]
Phase 2 trial evaluating nab-paclitaxel and bevacizumab followed by bevacizumab and erlotinib in metastatic breast cancer; completed with re…
-
CLINICAL_TRIALS trial_result · 2018-12-04Clinical Trial Update: Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients [Phase 1]
Phase 1 study evaluating LDE225 (sonidegib) in combination with docetaxel in advanced triple-negative breast cancer has completed with resul…
-
CLINICAL_TRIALS trial_result · 2018-11-08Clinical Trial Update: Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer [Phase 2]
Phase 2 trial update evaluating apatinib with paclitaxel and carboplatin as neoadjuvant therapy for locally advanced triple-negative breast …
-
CLINICAL_TRIALS trial_result · 2018-11-05Clinical Trial Update: A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) [Phase 1]
Phase 1 dose exploration study of birabresib (MK-8628) in selected advanced solid tumors (NMC, TNBC) was terminated; results posted in 2018.
-
CLINICAL_TRIALS withdrawal · 2018-10-22Clinical Trial Update: Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer [Phase 3]
Phase 3 trial investigating enzalutamide with paclitaxel vs placebo with paclitaxel in advanced triple-negative breast cancer was withdrawn.